Article Information
History
- February 8, 2022.
Article Versions
- Version 1 (February 7, 2022 - 22:30).
- You are currently viewing Version 2 of this article (February 8, 2022 - 08:48).
- View Version 3, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Stijn P. Andeweg1,
- Brechje de Gier1,
- Dirk Eggink1,
- Caroline van den Ende1,
- Noortje van Maarseveen2,3,
- Lubna Ali2,
- Boris Vlaemynck4,
- Raf Schepers4,
- RIVM COVID-19 surveillance and epidemiology team,
- Susan J.M. Hahné1,
- Chantal Reusken1,
- Hester E. de Melker1,
- Susan van den Hof1 and
- Mirjam J. Knol1,*
- 1Center for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands
- 2Saltro Diagnostic Center for Primary Care, Utrecht, The Netherlands
- 3Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, the Netherlands
- 4SYNLAB, Heppignies, Belgium
- ↵* Corresponding author; email: mirjam.knol{at}rivm.nl
Posted February 08, 2022.
Protection of COVID-19 vaccination and previous infection against Omicron BA.1 and Delta SARS-CoV-2 infections, the Netherlands, 22 November 2021- 19 January 2022
